Ustekinumab Biosimilar (NeuClone/Serum Institute of India)
乌司奴单抗生物类似药（NeuClone/Serum Institute of India）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameUstekinumab Biosimilar (NeuClone/Serum Institute of India)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeucloneSerum Institute Of India Ltd
China Registration ClassN/A
Develop Information
Active CompaniesNeucloneSerum Institute Of India Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A